CC 241108 17.50P (CC241108P17500) Stock Options, News & Quotes

US OptionsDetailed Quotes

CC241108P17500

Watchlist

0.05
0.000.00%

15min DelayTrading Nov 5 11:50 ET

0.05High0.05Low

Intraday

5D
Daily

News

Chemours Is Maintained at Equal-Weight by Morgan Stanley
Dow JonesNov 5 08:31 ET · Ratings
Chemours Analyst Ratings
BenzingaNov 5 08:20 ET · Ratings
Express News | Chemours Co : Morgan Stanley Cuts Target Price to $25.00 From $30.00
ReutersNov 5 06:13 ET
Should You Investigate The Chemours Company (NYSE:CC) At US$20.58?
Yahoo FinanceNov 5 05:20 ET
Barclays Maintains The Chemours(CC.US) With Hold Rating, Raises Target Price to $23
Moomoo NewsNov 5 04:34 ET · Ratings
Mizuho Securities Maintains The Chemours(CC.US) With Hold Rating
Moomoo NewsNov 5 01:32 ET · Ratings

Comments

SpyderCall

Jun 5 16:57

This turned out to be a great short, so far.

$The Chemours (CC.US)$
$SPDR S&P 500 ETF (SPY.US)$

SpyderCall: Options Action in This Ticker was Skewed Heavily on the Bearish Side Today

SpyderCall

May 29 22:00

Options Action in This Ticker was Skewed Heavily on the Bearish Side Today

$The Chemours (CC.US)$
Unusual Options Activity
There was an unusual amount of activity on the options chain for The Chemours company. Most of the activity was on the put side. You can see this in the heavily skewed put to call ratio in the picture directly below. A lopsided put/call ratio like this doesn't show the full picture. We need to find out if the puts were bought or sold to know if the activity was bullish or bear...

Dow tops 40,000 for the first time: Will the U.S. market rally march on?

Movers and Shakers

Mar 28 07:32

Columns Today's Morning Movers and Top Ratings: EL, BAC, ALL, RH and More

Morning Movers
Gapping up
$Estee Lauder (EL.US)$ Shares soared over 3% following an upgrade to buy from neutral by Bank of America, which referenced the company's profitability recovery efforts, new products, and growing market share in the prestige beauty sector.
$Allstate (ALL.US)$ The insurance stock climbed 0.9% after HSBC raised its rating to buy from hold, with analyst Vikram Gandhi commending the company's "decisive management...

Moomoo AI

Mar 27 18:02

The revelation of material weaknesses in Chemours' financial reporting and the manipulation of vendor payments and receivables by top executives could negatively impact investor confidence and the company's stock price.

Chemours Finds Material Weaknesses After Internal Review, Stock Slumps ~11% After Hours

Moomoo AI

Mar 27 16:49

Chemours' ongoing investigation and executive suspension could hurt investor confidence and stock price, despite a narrower Q4 loss and higher revenue.

Chemours Responds to Regulators, Prosecutors About Internal Audit